Condition: Uterine Fibroids · Endometriosis · Sponsor: Sumitomo Pharma Switzerland GmbH
The purpose of this clinical trial to characterize changes in bone mineral density during continuous treatment with relugolix combination tablet for up to 48 months (4 years) and 1 year of post-treatment follow-up in premenopausal women with heavy menstrual bleeding associated with uterine leiomyomas (fibroids) or with moderate-to-severe pain associated with endometriosis.
This description comes directly from the study's public registry record.
Clinical Trials at Myovant · 650-278-8743 · ClinicalTrials@Myovant.com
Always discuss trial participation with your own doctor first.
| Mobile | Mobile, Alabama, United States | Recruiting |
| Chandler | Chandler, Arizona, United States | Recruiting |
| Mesa | Mesa, Arizona, United States | Recruiting |
| Peoria | Peoria, Arizona, United States | Recruiting |
| Phoenix | Phoenix, Arizona, United States | Recruiting |
| Tucson | Tucson, Arizona, United States | Recruiting |
| Burbank | Burbank, California, United States | Recruiting |
| Canoga Park | Canoga Park, California, United States | Recruiting |
| Encinitas | Encinitas, California, United States | Recruiting |
| Inglewood | Inglewood, California, United States | Recruiting |
| Lomita | Lomita, California, United States | Recruiting |
| Long Beach | Long Beach, California, United States | Recruiting |
+ 108 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05862272